Proactive: Race Oncology On Track For Clinical Trials Following ‘Excellent’ RC220 Bisantrene Safety And Toxicology Results
Proactive: Race Oncology On Track For Clinical Trials Following ‘Excellent’ RC220 Bisantrene Safety And Toxicology Results
Race CEO Dr Daniel Tillett spoke with Johnathan Jackson at Proactive about the completion of GLP studies for RC220 bisantrene. Dr Tillett noted that the studies demonstrated excellent safety profile for RC220 bisantrene. It...
The Australian: Race Moves Closer To Phase 1 Trial With Key CRO Appointment
The Australian: Race Moves Closer To Phase 1 Trial With Key CRO Appointment
The Australian reports that Race Oncology has appointed George Clinical as the Contract Research Organisation to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients. Read the full article here....
Motley Fool: ASX Healthcare Stock Surges 11% On ‘Incredibly Valuable’ FDA News
Motley Fool: ASX Healthcare Stock Surges 11% On ‘Incredibly Valuable’ FDA News
The Motley Fool reports on the exciting news that Race has received today. The US Food and Drug Administration (FDA) has extended Rare Paediatric Disease Designation to RC220 bisantrene for the treatment of paediatric...
The Australian: Race Oncology Stock Gains On US FDA Milestone
The Australian: Race Oncology Stock Gains On US FDA Milestone
The Australian reports that The US Food and Drug Authority (FDA) has extended Rare Paediatric Disease Designation (RPDD) to Race’s oncology drug RC220 bisantrene for paediatric acute myeloid leukemia (AML). The RPDD in paediatric...
Proactive: Race Oncology At 12-Month High On Promising Preclinical Results For Drug Combination In Multiple Myeloma Treatment
Proactive: Race Oncology At 12-Month High On Promising Preclinical Results For Drug Combination In Multiple Myeloma Treatment
Proactive reports that Race has hit a new 12-month high on fielding some strong preclinical findings on the efficacy of lead asset bisantrene in treating multiple myeloma. Race CEO Dr Daniel Tillett commented: “The potential...
Proactive: Race Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220
Proactive: Race Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220
The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Race CEO Dr Daniel Tillett spoke with Proactive about this significant...
Sharewise Webinar With CEO Dr Daniel Tillett
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Race Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability...
Demystifying Clinical Trials & Approval Processes
Demystifying Clinical Trials & Approval Processes
In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Race Oncology’s journey through the drug development process. Dr Tillett...
The “Race” To Beat Cancer
The “Race” To Beat Cancer
Race CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year. Dr Tillett...
Race CEO Discusses Benefits Of Resurrecting Abandoned Drugs With Stockhead
Race CEO Discusses Benefits Of Resurrecting Abandoned Drugs With Stockhead
Race CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to whether a drug makes...
